Incubation of platelets, neutrophils, and lymphoma cells with Descemet's membranes of bovine corneas and with the extracellular matrix (ECM) produced by cuftured corneal endothelial cells resulted in release of basic fibroblast growth factor (bFGF), which stimulated the proliferation of 3T3 fibroblasts and vascular endothelial cells. Similar requirements were observed for release of endogenous bFGF stored in Descemet's membrane and of exogenous bFGF sequestered by the subendothelial ECM. Release of ECM-resident bFGF by platelets, neutrophils, and lymphoma cells was inhibited by carrageenan lambda, but not by protease inhibitors, in correlation with the inhibition of heparanase activity expressed by these cells. Degradation of the ECMheparan sulfate side chains by this endo-j8-D-glucuronidase is thought to play an important role in cell invasion, particularly in the extravasation of blood-borne tumor cells and activated cells of the immune system. We propose that both heparanase and ECM-resident bFGF may modulate the cell response to contact with its local environment. Heparanase-mediated release of active bFGF from storage in basement membranes provides a novel mechanism for a localized induction of neovascularization in various normal and pathological processes, such as wound healing, inflammation, and tumor development.
Fibroblast growth factors (FGF) are a family of structurally related polypeptides characterized by high affinity to heparin (Gospodarowicz et al., 1987; Burgess and Maciag, 1989; Rifkin and Moscatelli, 1989) . They are highly mitogenic for vascular endothelial cells (EC) and are among the most potent inducers of neovascularization and mesenchyme formation (Kimelman and Kirschner, 1987) . Basic fibroblast growth factor (bFGF) has been extracted from the subendothelial extracellular matrix (ECM) produced in vitro (Baird and Ling, 1987; Vlodavsky et al., 1987) and from basement membranes of the cornea (Folkman et al., 1988) , suggesting that ECM may serve as a reservoir for bFGF. In fact, immunohistochemical staining revealed the localization of bFGF in basement membranes of diverse tissues of the rat fetus (Gonzalez et al., 1990) and of blood vessels of human tissues (CardonCardo et al., 1990) , as well as in nuclei, intercalated discs, and endomysium of bovine heart muscle fibers (Kardami and Fandrich, 1989) . Acidic FGF has been shown to be deposited into the ECM produced by cardiac myocytes (Weiner and Swain, 1989) . Despite the ubiquitous presence of bFGF in normal tissues, EC proliferation in these tissues is usually very low (Denekamp, 1984) , suggesting that bFGF is somehow sequestered from its site of action. Studies on the interaction of bFGF with ECM revealed that bFGF binds to heparan sulfate proteoglycans (HSPG) in the ECM and can be released by heparin-like molecules, heparan sulfate (HS)-degrading enzymes (Bashkin et al., 1989) , or plasmin (Saksela and Rifkin, 1990) . These results suggest that the ECM HSPG provide a natural storage depot for bFGF and possibly other growth-promoting factors. Displacement of bFGF from its storage within basement membranes and ECM may provide a novel mechanism for induction of neovascularization in normal and pathological situations (Baird and Walicke, 1989; Vlodavsky et al., 1990) . Such a role can be ascribed to an endo-f3-D-glucuronidase (heparanase) that degrades HS side chains in the subendothelial ECM (Vlodavsky et al., 1983; Nakajima et al., 1988) . Expression of heparanase has been correlated with the ability of blood-borne tumor cells (Vlodavsky et al., 1983; Nakajima et al., 1988) , neutrophils (Matzner et al., 1985) , and activated cells of the immune system (Naparstek et al., 1984) to extravasate in processes such as tumor metastasis, inflammation, and autoimmunity. In the present study, we demonstrate that heparanase can be utilized by various cell types to release active bFGF from the subendothelial ECM, both in vitro and in vivo. 
Results
We have previously demonstrated that exposure of ECM to either bacterial heparitinase, native heparin, or heparin-like molecules resulted in release of ECM-bound bFGF (Bashkin et al., 1989) . Heparin and various nonanticoagulant species of heparin are also potent inhibitors of heparanase activity (Bar-Ner et al., 1987) . To investigate whether heparanase expressed by various cell types is involved in release of bFGF from ECM, we first screened for molecules that inhibit the enzyme but, unlike heparin, do not release the ECM-bound bFGF. For this purpose ECM was incubated with 1251-bFGF, washed free of unbound FGF, and incubated with various low-Mr and modified species of heparin to evaluate the extent of bFGF release from ECM. Oligosaccharides derived from depolymerized heparin were inadequate, because molecules as small as the hexasaccharide efficiently released 1251-FGF from ECM (Bashkin et al., 1989 heparanase activity and release of ECM-bound bFGF. Among these compounds, carrageenan lambda was found to inhibit the enzyme efficiently at concentrations that induced little or no release of bFGF from ECM (Table 1) . Because this compound yielded the best differential effect, it was used in subsequent experiments to investigate the involvement of cellular heparanase in release of bFGF from the subendothelial ECM produced in vitro and from Descement's membrane of bovine corneas. Whereas the ECM system was used as a model for release of exogenously added bFGF, bovine corneas were utilized to study release of endogenous bFGF from basement membranes.
Release of ECM-bound FGF by platelets Incubation (3 h, 37°C) of increasing amounts of lysed platelets with ECM that was first incubated with 1251-bFGF resulted in release of up to 600/o of the ECM-bound FGF in a dose-dependent manner ( Figure 1 ). This release was inhibited by 85-95% in the presence of 10 ,ug/ml carrageenan lambda (Figures 1 and 2 ), which also completely inhibited release of HS degradation products by means of the platelet heparitinase ( Figure 3A ). In contrast, both degradation of HS and release of ECM-bound bFGF were not inhibited in the presence of carrageenan kappa. We have previously demonstrated that HS in subendothelial ECM is available for degradation by the platelet heparitinase (Yahalom et al., 1984) . Carrageenan lambda, but not protease inhibitors (2 mM PMSF and 100 KIU/ml aprotinin), inhibited both degradation of HS ( Figure 3A ) and release of ECM-bound bFGF by lysed (Figure 2 ) or intact (Figure 4) jig/ml trypsin under the same conditions. This proteolytic activity was inhibited by protease inhibitors, but there was no effect to carrageenan. Effect of carrageenan and protease inhibitors on heparanase-mediated degradation of HS in ECM. Sulfate-labeled ECM (35-mm plates) was incubated (3 h, 370C, pH 6.8) with (A) 2.5 x 1 o8 platelets; (B) supernate fraction of 5 x 1 o6 neutrophils that were preincubated (4 h) at 4°C; and (C) 5 x 1 o6 intact neutrophils. Incubations on the labeled ECM were performed in the absence (m) or presence of either 10 vg/ml carrageenan lambda (0) or a mixture of protease inhibitors (2 mM PMSF, 10 gg/ml leupeptin, 100 KlU/ml aprotinin, 100,ug/ml benzamidine, and 5 mM EGTA) (A).
The ECM was also incubated with PBS alone in the absence of cells (L). Labeled degradation products released into the incubation medium were analyzed by gel filtration on Sepharose 6B, as described in Materials and methods. Figure  4 ) and HS degradation fragments from the ECM ( Figure 3A ).
Release of ECM-bound FGF by neutrophils Human polymorphonuclear neutrophils (PMN) express heparanase activity, which degrades heparan sulfate in the subendothelial ECM (Matzner et aL, 1985) . The enzyme is found mainly in the PMN-specific granules, and up to 250/o of its cellular content is preferentially released on incubation of the cells at 40C (Matzner et al., 1985) . As demonstrated in Figure 3B , 836 degradation of the ECM HS by the released enzyme(s) was, unlike degradation by intact neutrophils ( Figure 3C ), inhibited by protease inhibitors. These inhibitors had no effect on the neutrophil heparanase itself, but rather inhibited the activity of protease(s) that generated a more accessible substrate for subsequent degradation by the heparanase enzyme (Matzner et al., 1985; Bar-Ner et al., 1986) . This type of sequential degradation is reflected by the accumulation of high-Mr labeled material in the presence of carrageenan but not of protease inhibitors, which inhibited release from ECM of both high-and low-Mr material ( Figure 3B) . We compared the effect of carrageenan and protease inhibitors on degradation of HS ( Figure 3 ) and release of ECM-bound FGF (Figure 4 ) by intact neutrophils and by a neutrophil supernate fraction. As demonstrated in Figure 4 , supernate fraction obtained after incubation (4 h) of human neutrophils at 4°C released 70% of the ECM-bound 1251-bFGF. This release was inhibited by -80% (not taking into account spontaneous release from ECM alone) in the presence of either carrageenan lambda or protease inhibitors, in correlation with the inhibition of HS degradation under the same conditions ( Figure 3B ). Incubation of ECM with intact neutrophils resulted in degradation of HS ( Figure  3C ) and release of 1251-bFGF ( Figure 4 ) to an extent that was similar to that obtained by the neutrophil supernatant. Release of ECM-bound bFGF by intact PMN was inhibited by carrageenan, although to a smaller extent (55%) compared with the neutrophil supernatant. There was only a small inhibitory effect to a mixture of protease inhibitors (Figure 4 ), as was also observed when intact PMN were incubated with sulfate-labeled ECM under the same conditions ( Figure 3C ).
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We have previously reported that the ECM produced by cultured corneal EC contains bFGF that promotes cell proliferation and differentiation Rogelj et aL, 1989 (Folkman et al., 1988; Bashkin et aL, 1989 ).
Descemet's membrane has been shown to contain -10-fold higher amounts of bFGF per unit area, compared with its in vitro counterpart, the ECM produced by corneal EC (Folkman et aL, 1988) . Based on the mitogenic activity of corneal extracts compared with recombinant bFGF, it was estimated that the average amount of bFGF per cornea ranged from 30 to 40 ng. Incubation of washed platelets on top of the Descemet's membrane surface of bovine corneas resulted in a time-dependent release of growth-promoting activity for 3T3 fibroblasts ( Figure 6) (Rogelj et al., 1989) . Apart from its storage in the subendothelial from deposition by cells that synthesize the ECM, bFGF liberated in response to cell damage or death is likely to be sequestered by the ECM ssion HS and is thereby stabilized and protected (Gospodarowicz and Cheng, 1986 ; Saksela et ive previously reported that the subena/, 1988). As demonstrated in the present lial ECM and Desstudy, both endogenous and exogenously :'s membranes of bovine corneas (Folkadded bFGF were accessible to release by hep-,t al., 1988) contain bFGF-like factors that aranase-although a more efficient release of ipate in induction of cell proliferation and bFGF (up to 70% of the ECM-bound factor) was hntiation by the ECM (Rogelj et al., 1989) . achieved in the case of added bFGF compared ve also demonstrated that bFGF is bound with endogenous bFGF, where up to about 20% in the ECM and is readily released when of the total amount of factor was released. 'M HS is degraded by heparanase (BashThese results may reflect the different requireal., 1989). Release of FGF was also ments for release of surface-bound factors, as ht about by native heparin and by various opposed to bFGF that is deeply embedded in in-like molecules that bind FGF with high the tissue. It should be emphasized, however, {compared with HS in the ECM (Bashkin that the estimated amounts of endogenous 1989). In the present study, we investibFGF released from corneas during incubation the ability of various normal and malignant with cells are physiologically relevant, because o release bFGF from the subendothelial bFGF has been shown to induce EC proliferation and, in particular, the involvement of a and angiogenesis at picomolar (1-10 ng/ml) ir endoglycosidase (heparanase) in this amounts . Ree. Heparanase activity correlates with the gardless of the source of heparanase and of of blood-borne tumor cells and activated whether release of bFGF was brought about by
If the immune system to leave the circua pure enzyme, intact cells, or cell lysates, inand reach their target sites (Parish et al., hibition of FGF release correlated with inhibition Nakajima et al., 1988; Lider et al., 1990 (Vlodavsky et al., 1983; Nakajima et al., 1988) , but also, may at the same time, elicit an indirect neovascular response by means of releasing the ECM-resident FGF. Likewise, platelets and activated cells of the immune system (i.e., macrophages, neutrophils, and T lymphocytes) (Naparstek et al., 1984; Yahalom et al., 1984; Matzner et aL, 1985) that are often attracted by tumor cells may indirectly stimulate tumor angiogenesis by means of their heparanase activity. These cells may also elicit an angiogenic response in the process of inflammation and wound healing. We have recently reported that mast cells express heparanase activity . It is conceivable that mast cell heparin and/or heparanase may be involved in angiogenesis by liberating the ECM-resident bFGF. Mast cells are widely distributed in perivascular connective tissues, especially in areas of active tumor growth and vascular reactivity. Heparanase, released on degranulation of mast cells , may thus play a role in the longproposed mast cell-mediated stimulation of neovascularization (Kessler et al., 1976) .
Several studies and our own results indicate that heparin and HS inhibit the mitogenic activity of bFGF but at the same time stabilize and protect the molecule from inactivation (Gospodarowicz and Cheng, 1986; Saksela et al., 1988) .
It is therefore conceivable that bFGF is stored in ECM in a highly stable but relatively inactive form, as also indicated by the highly stable ECM-resident growth-promoting activity compared with that of bFGF in a fluid phase (Fridman Vol. 1, October 1990 et al., 1985) . Release from ECM of bFGF as a complex with HS fragment may yield a form of bFGF that is more stable than free bFGF and yet capable of binding the high-affinity plasmamembrane receptors (Saksela et al., 1988) . Moreover, bFGF complexed to HS fragment should diffuse through the stroma to the target cells more readily than free bFGF because bFGF-HS complexes do not bind to the ECM (Rifkin and Moscatelli, 1989) . Although the present study emphasizes the role of heparanase in bFGF release, it does not exclude the involvement of other enzymes. Thus, ECMbound bFGF is released by plasmin as a noncovalent complex with HSPG or glycosaminoglycans (GAG) (Saksela and Rifkin, 1990) . Basic FGF complexed to HSPG stimulates production of plasminogen activator (PA) by EC (Saksela et al., 1988) , possibly yielding an autocatalytic process (Saksela and Rifkin, 1990 ). Moreover, heparanase-mediated degradation of ECMbound HS has been shown to be facilitated markedly by both cellular and ECM-associated PA (Bar-Ner et al., 1986) . Whereas proteolytic digestion of the ECM releases bFGF (Bashkin et al., 1989; Saksela and Rifkin, 1990 )-but at the same time degrades major constituents of the ECM, resulting in significant structural and functional alterations-heparanase activity is restricted to cleavage of HS side chains so that the treated ECM retains, to a large extent, its native morphological appearance and biological activity.
In addition to bFGF, both granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 also bind to HS on stromal cells (Roberts et al., 1988) . These factors may be released by heparanase and presented to hematopoietic cells. It has also been reported that both TGF-3 and its proteoglycan receptor (Betaglycan) are present in the ECM of various cells and tissues (Andres et al., 1989) . Likewise, various heparin-binding growth factors are tightly associated with bone matrix. Among these is osteogenin, an ECM-associated boneinductive protein that was isolated from demineralized bone by heparin affinity chromatography (Sampath et al., 1987) . Heparanase may thus participate in cellular responses to interaction with the local environment by means of releasing active growth and differentiation factors that are firmly sequestered by HS in the ECM.
Materials and methods Materials
Partially purified bFGF was isolated from bovine brain, as described (Gospodarowicz et al., 1978 
Cells
Cultures of bovine corneal endothelial cells were established from steer eyes as previously described (Gospodarowicz et al., 1977) . Stock cultures were maintained in DMEM supplemented with 100/0 bovine calf serum, 5% FCS, penicillin (50 U/ml), and streptomycin (50 jg/ml) at 370C in 100/0 C02 humidified incubators. Brain-derived bFGF (100 ng/ml) was added every other day during the phase of active cell growth. Bovine aortic endothelial cells (BAEC) were cultured as described . Mouse methylcholanthreneinduced ESb T lymphoma cells were cultured as described (Vlodavsky et al., 1983) .
Preparation of platelet-rich plasma (PRP)
Blood from healthy individuals who had a history of no drug ingestion for at least 10 d before testing was obtained by venipuncture with the two-syringe technique and mixed with 0.1 vol of 3.2% trisodium citrate (Yahalom et al., 1984 platelets/,4l (Yahalom et al., 1984) .
Neutrophils
Neutrophils were prepared from fresh blood samples obtained from healthy human donors and were purified by dextran sedimentation followed by hypotonic lysis of contaminating erythrocytes and centrifugation over Ficoll-Hypaque, as described (Matzner et al., 1985) . trophils. Preferential release of the neutrophil heparanase was obtained by incubation of the cell suspension at 40C for 4 h, followed by low-speed centrifugation (300 g, 10 min). The supernate fraction contained 20-300/o of the total cellular heparanase activity (Matzner et al., 1985) . Samples (0.2-0.4 ml) of this supernatant were taken for determinations of bFGF release and heparanase activity.
Preparation of dishes coated with ECM
Bovine corneal endothelial cells were dissociated from stock cultures (2nd-5th passage) with STV and plated into 35-mm or 4-well plates at an initial density of 5 x 104 cells/ml. Cells were maintained as described above, except that 5% dextran T-40 was included in the growth medium. Six-8 d after the cells reached confluency, we exposed the subendothelial ECM by dissolving (3 min, 22°C) the cell layer with a solution containing 0.50/% Triton X-100 and 20 mM NH40H in PBS followed by four washes in PBS . For preparation of sulfate-labeled ECM, we
added Na235S]O4 (40 uCi/ml) 3 and 7 d after seeding the cells, and the cultures were incubated with the label with no medium change. Ten-1 2 d after seeding, we dissolved the cell layer and exposed the ECM as described above. Of the total ECM-associated radioactivity, 70-750/o was incorporated into HS side chains (Kramer et al., 1982; Vlodavsky et al., 1983) . The ECM remained intact, free of cellular debris, and firmly attached to the entire area of the tissue culture dish. The presence of nuclei or cytoskeletal elements could not be detected in the denuded ECM when plates were examined by phase-contrast microscopy, scanning electron microscopy, or indirect immunofluorescence using anti-actin and anti-vimentin antibodies or the benzimidazole derivative Hoechst 33258 for nuclear staining. No serum proteins could be identified in the ECM (Gospodarowicz et al., 1983) . Main constituents of the corneal endothelial ECM were fibronectin; laminin; collagen types 1, Ill, and IV; elastin; and sulfated proteoglycans (i.e., heparan sulfate, dermatan sulfate, and chondroitin sulfate proteoglycans).
Degradation of sulfated proteoglycans
[35J04,-labeled ECM was incubated (3 h, 370C, 100/0 CO2 incubator) with intact cells, cell lysates, or heparanase preparations in PBS containing 0.020/o gelatin adjusted to pH 6.8 with 20 mM phosphate buffer. To evaluate the occurrence of proteoglycan degradation, the incubation medium was collected and applied for gel filtration on Sepharose 6B columns (0.9 x 30 cm). Fractions (0.2 ml) were eluted with PBS at a flow rate of 5 ml/h and counted for radioactivity using Bio-fluor scintillation fluid. The excluded volume (V.) was marked by blue dextran and the total included volume (VJ) by phenol red. The latter was shown to comigrate with free [35S]04= (Kramer et al., 1982; Vlodavsky et al., 1983; Matzner et al., 1985) . Degradation fragments of HS side chains eluted from Sepharose 6B at 0.5 < Kav < 0.8 (peak 11) (Kramer et al., 1982; Vlodavsky et al., 1983) . A nearly intact HSPG released from ECM by trypsin-and, to a lower extent, during incubation with PBS alone-was eluted next to V. (peak 1) (Vlodavsky et al., 1983 (Bashkin et al., 1989 Ml of 0.1 mM KI. The reaction mixture was applied onto a small (0.3 ml) heparin-Sepharose column and the '251-FGF eluted with 1.5 ml buffer containing 20 mM sodium phosphate, pH 7.2, 2 M NaCI, and 0.2% gelatin. The specific activity was usually 1.2 x 105 cpm/ng FGF and the labeled preparation was kept for up to 3 wk at 40C. The iodinated material yielded a single band (18.4 kDa) when subjected to NaDodSO4-PAGE and autoradiography.
Release of ECM-bound FGF ECM-coated wells (4-well plates) were ir\cubated with either unlabeled bFGF (20 ng in 0.5 ml DMEM per well, overnight, 40C) or with iodinated FGF (1.5-2.5 x 10' cpm/well, 3 h, room temperature) and the unbound factor washed four times with PBS containing 0.02% gelatin. ECM was then incubated (3 h, 37°C) with intact cells, cell lysates, or heparanase preparations; and aliquots (20 Al) of the 0.5 ml incubation medium were tested for mitogenic activity on 3T3 fibroblasts and vascular EC, or amount of released iodinated material. The remaining ECM was washed twice with PBS and solubilized with 1 M NaOH, and the radioactivity was counted in a y-counter. The percentage of released 1251-FGF was calculated from the total ECM-associated radioactivity.
"Spontaneous" release in the presence of incubation medium alone was 7-12% of the total ECM-bound bFGF. Each data point is the average of triplicate wells, and the standard deviation did not exceed 6%. Intact cells and heparanase preparations were incubated under the same conditions with sulfate-labeled ECM, and the released radioactivity was analyzed for presence of HS degradation products, as described above.
Release of FGF from bovine corneas
Bovine corneas were placed in 35-mm culture dishes with their Descemet's membrane side upwards. The corneas were washed three times in PBS and incubated (37°C) with 0.5 ml of PBS (0.02% gelatin) alone, intact cells, or cell lysates. The incubation mixtures were tested for stimulation of 3H-thymidine incorporation by 3T3 cells and proliferation of vascular EC. Mitogenic activity released from corneas in the presence of PBS alone did not exceed 20% of that released by intact or lysed cells.
Growth factor activity
Assay for DNA synthesis in 3T3 cells was performed as described (Goldman and Bar-Shavit, 1979 ).
